Header Logo

Connection

Beverly Sha to HIV-1

This is a "connection" page, showing publications Beverly Sha has written about HIV-1.
Connection Strength

2.169
  1. Utility of the Signal-to-Cutoff Ratio and Antigen Index from Fourth- and Fifth-Generation HIV-1/HIV-2 Antigen/Antibody Assays for the Diagnosis of Acute HIV Infection: Applicability for Real-Time Use for Immediate Initiation of Antiretroviral Therapy. J Clin Microbiol. 2022 12 21; 60(12):e0120422.
    View in: PubMed
    Score: 0.689
  2. Postpartum viral load rebound in HIV-1-infected women treated with highly active antiretroviral therapy: AIDS Clinical Trials Group Protocol A5150. HIV Clin Trials. 2011 Jan-Feb; 12(1):9-23.
    View in: PubMed
    Score: 0.302
  3. ?-catenin regulates HIV latency and modulates HIV reactivation. PLoS Pathog. 2022 03; 18(3):e1010354.
    View in: PubMed
    Score: 0.164
  4. Canonical Wnts Mediate CD8+ T Cell Noncytolytic Anti-HIV-1 Activity and Correlate with HIV-1 Clinical Status. J Immunol. 2020 10 15; 205(8):2046-2055.
    View in: PubMed
    Score: 0.148
  5. Absence of virological changes after acute febrile illnesses in two patients with undetectable pre-illness plasma HIV-1-RNA levels. AIDS. 2000 Apr 14; 14(6):746-8.
    View in: PubMed
    Score: 0.144
  6. Evaluation of immunologic markers in cervicovaginal fluid of HIV-infected and uninfected women: implications for the immunologic response to HIV in the female genital tract. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Nov 01; 16(3):161-8.
    View in: PubMed
    Score: 0.121
  7. HIV-1-infected peripheral blood mononuclear cells enhance neutrophil survival and HLA-DR expression via increased production of GM-CSF: implications for HIV-1 infection. J Acquir Immune Defic Syndr. 2011 Jan 01; 56(1):16-25.
    View in: PubMed
    Score: 0.075
  8. HIV-1-infected antiretroviral-treated patients with prolonged partial viral suppression: clinical, virologic, and immunologic course. J Acquir Immune Defic Syndr. 2003 Dec 15; 34(5):491-6.
    View in: PubMed
    Score: 0.046
  9. Antibody-dependent cell-mediated cytotoxicity in cervical lavage fluids of human immunodeficiency virus type 1--infected women. J Infect Dis. 2002 Feb 15; 185(4):439-47.
    View in: PubMed
    Score: 0.041
  10. Myeloid-related protein (MRP)-8 from cervico-vaginal secretions activates HIV replication. AIDS. 2001 Mar 09; 15(4):441-9.
    View in: PubMed
    Score: 0.038
  11. CD32 is enriched on CD4dimCD8bright T cells. PLoS One. 2020; 15(9):e0239157.
    View in: PubMed
    Score: 0.037
  12. Association of indicators of bacterial vaginosis with a female genital tract factor that induces expression of HIV-1. AIDS. 1999 Oct 01; 13(14):1905-12.
    View in: PubMed
    Score: 0.035
  13. Bacterial vaginosis-associated microflora isolated from the female genital tract activates HIV-1 expression. J Acquir Immune Defic Syndr. 1999 Jul 01; 21(3):194-202.
    View in: PubMed
    Score: 0.034
  14. Incorporation of zidovudine into leukocyte DNA from HIV-1-positive adults and pregnant women, and cord blood from infants exposed in utero. AIDS. 1999 May 28; 13(8):919-25.
    View in: PubMed
    Score: 0.034
  15. Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500?000 copies/mL: week 48 outcomes from ACTG 5353. J Antimicrob Chemother. 2019 05 01; 74(5):1376-1380.
    View in: PubMed
    Score: 0.034
  16. Levels of proinflammatory cytokines in plasma after pneumoccoccal immunization in human immunodeficiency virus type 1-infected patients. Clin Diagn Lab Immunol. 1999 May; 6(3):427-8.
    View in: PubMed
    Score: 0.034
  17. A human immunodeficiency virus (HIV)-inducing factor from the female genital tract activates HIV-1 gene expression through the kappaB enhancer. J Infect Dis. 1998 Nov; 178(5):1343-51.
    View in: PubMed
    Score: 0.032
  18. Mechanisms of resistance of HIV-1 primary isolates to complement-mediated lysis. Virology. 1998 Jul 05; 246(2):370-8.
    View in: PubMed
    Score: 0.032
  19. ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL. Clin Infect Dis. 2018 05 17; 66(11):1689-1697.
    View in: PubMed
    Score: 0.031
  20. A potent activator of HIV-1 replication is present in the genital tract of a subset of HIV-1-infected and uninfected women. AIDS. 1997 Sep; 11(11):1319-26.
    View in: PubMed
    Score: 0.030
  21. Immunologic and virologic evaluation after influenza vaccination of HIV-1-infected patients. AIDS. 1997 Jul; 11(8):1013-21.
    View in: PubMed
    Score: 0.030
  22. Susceptibility of HIV-1 plasma virus to complement-mediated lysis. Evidence for a role in clearance of virus in vivo. J Immunol. 1996 Aug 15; 157(4):1791-8.
    View in: PubMed
    Score: 0.028
  23. Age-related immune dysfunction in health and in human immunodeficiency virus (HIV) disease: association of age and HIV infection with naive CD8+ cell depletion, reduced expression of CD28 on CD8+ cells, and reduced thymic volumes. J Infect Dis. 2003 Jun 15; 187(12):1924-33.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.